Cargando…

Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?

SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for ballo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, K. L., Beall, D. P., Frohbergh, M., Lau, E., Hirsch, J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394540/
https://www.ncbi.nlm.nih.gov/pubmed/29063215
http://dx.doi.org/10.1007/s00198-017-4281-z
_version_ 1783398917960892416
author Ong, K. L.
Beall, D. P.
Frohbergh, M.
Lau, E.
Hirsch, J. A.
author_facet Ong, K. L.
Beall, D. P.
Frohbergh, M.
Lau, E.
Hirsch, J. A.
author_sort Ong, K. L.
collection PubMed
description SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for balloon kyphoplasty (BKP) and vertebroplasty (VP) patients. INTRODUCTION: BKP and VP are associated with lower mortality risks than non-surgical management (NSM) of VCF. VP versus sham trials published in 2009 sparked controversy over its effectiveness, leading to diminished referral volumes. We hypothesized that lower BKP/VP utilization would lead to a greater mortality risk for VCF patients. METHODS: BKP/VP utilization was evaluated for VCF patients in the 100% US Medicare data set (2005–2014). Survival and morbidity were analyzed by the Kaplan-Meier method and compared between NSM, BKP, and VP using Cox regression with adjustment by propensity score and various factors. RESULTS: The cohort included 261,756 BKP (12.6%) and 117,232 VP (5.6%) patients, comprising 20% of the VCF patient population in 2005, peaking at 24% in 2007–2008, and declining to 14% in 2014. The propensity-adjusted mortality risk for VCF patients was 4% (95% CI, 3–4%; p < 0.001) greater in 2010–2014 versus 2005–2009. The 10-year risk of mortality for the overall cohort was 85.1%. BKP and VP cohorts had a 19% (95% CI, 19–19%; p < 0.001) and 7% (95% CI, 7–8%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the NSM cohort, respectively. The BKP cohort had a 13% (95% CI, 12–13%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the VP cohort. CONCLUSIONS: Changes in treatment patterns following the 2009 VP publications led to fewer augmentation procedures. In turn, the 5-year period following 2009 was associated with elevated mortality risk in VCF patients. This provides insight into the implications of treatment pattern changes and associated mortality risks.
format Online
Article
Text
id pubmed-6394540
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-63945402019-03-15 Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Ong, K. L. Beall, D. P. Frohbergh, M. Lau, E. Hirsch, J. A. Osteoporos Int Original Article SUMMARY: The 5-year period following 2009 saw a steep reduction in vertebral augmentation volume and was associated with elevated mortality risk in vertebral compression fracture (VCF) patients. The risk of mortality following a VCF diagnosis was 85.1% at 10 years and was found to be lower for balloon kyphoplasty (BKP) and vertebroplasty (VP) patients. INTRODUCTION: BKP and VP are associated with lower mortality risks than non-surgical management (NSM) of VCF. VP versus sham trials published in 2009 sparked controversy over its effectiveness, leading to diminished referral volumes. We hypothesized that lower BKP/VP utilization would lead to a greater mortality risk for VCF patients. METHODS: BKP/VP utilization was evaluated for VCF patients in the 100% US Medicare data set (2005–2014). Survival and morbidity were analyzed by the Kaplan-Meier method and compared between NSM, BKP, and VP using Cox regression with adjustment by propensity score and various factors. RESULTS: The cohort included 261,756 BKP (12.6%) and 117,232 VP (5.6%) patients, comprising 20% of the VCF patient population in 2005, peaking at 24% in 2007–2008, and declining to 14% in 2014. The propensity-adjusted mortality risk for VCF patients was 4% (95% CI, 3–4%; p < 0.001) greater in 2010–2014 versus 2005–2009. The 10-year risk of mortality for the overall cohort was 85.1%. BKP and VP cohorts had a 19% (95% CI, 19–19%; p < 0.001) and 7% (95% CI, 7–8%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the NSM cohort, respectively. The BKP cohort had a 13% (95% CI, 12–13%; p < 0.001) lower propensity-adjusted 10-year mortality risk than the VP cohort. CONCLUSIONS: Changes in treatment patterns following the 2009 VP publications led to fewer augmentation procedures. In turn, the 5-year period following 2009 was associated with elevated mortality risk in VCF patients. This provides insight into the implications of treatment pattern changes and associated mortality risks. Springer London 2017-10-24 2018 /pmc/articles/PMC6394540/ /pubmed/29063215 http://dx.doi.org/10.1007/s00198-017-4281-z Text en © The Author(s) 2017, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle Original Article
Ong, K. L.
Beall, D. P.
Frohbergh, M.
Lau, E.
Hirsch, J. A.
Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title_full Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title_fullStr Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title_full_unstemmed Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title_short Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
title_sort were vcf patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394540/
https://www.ncbi.nlm.nih.gov/pubmed/29063215
http://dx.doi.org/10.1007/s00198-017-4281-z
work_keys_str_mv AT ongkl werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials
AT bealldp werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials
AT frohberghm werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials
AT laue werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials
AT hirschja werevcfpatientsathigherriskofmortalityfollowingthe2009publicationofthevertebroplastyshamtrials